Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

About this update from Viking Therapeutics, Inc.

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 -- -- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 -- -- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 -- -- Strong Quarter-End Cash Position of $603 Million -- SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments. Highlights from the First Quarter Ended March 31, 2026, and Other Recent Events: "We are excited to report that the advances and strong momentum Viking created in 2025 have carried forward through the first quarter of 2026," stated Brian Lian, Ph.D., chief executive officer of Viking. "Looking ahead, we continue to execute the Phase 3 clinical development program for our lead obesity program VK2735. Our VANQUISH Phase 3 studies of the subcutaneous formulation are fully enrolled, and our planned Phase 3 studies with the oral tablet formulation are expected to begin later this year, marking a rapid pace of development for this important program. Our goal with these studies is to introduce the industry's first oral and subcutaneous dual GLP-1 and GIP co-agonist molecule for the treatment of obesity. Based on the results to date, we believe our product will have exceptional efficacy, safety, and tolerability. Concurrent with our Phase 3 activities, our novel maintenance dosing trial continues, and we expect to generate data from this study in the third quarter. With our earlier-stage pipeline, our amylin agonist continues to advance, and we expect to initiate a Phase 1 trial for the lead molecule VK3019 later this quarter. Operationally, as VK2735 continues to advance, our organization continues to evolve, as well. Our team has been executing a fiscally responsible and timely strategic expansion plan that ensures that Viking has the partnerships, vendors and in-house expertise required to succee...

View stock analysis, news, and events for Viking Therapeutics, Inc.